drugset / Trial / NCT07025551

A Clinical Study of MK-8527 in Participants With Mild and Moderate Hepatic Impairment (MK-8527-015)

NCT07025551

Phase 1 Completed 18 enrolled Merck Sharp & Dohme LLC
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to learn what happens to MK-8527 in a person's body over time (a pharmacokinetic \[PK\] study). Researchers will compare what happens to MK-8527 in the body when it is given to healthy participants and participants with mild and moderate hepatic (liver) impairment.

Timeline

Start
2025-09-19
Primary completion
2026-02-13
Completion
2026-02-13

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-8527 Small molecule Oral

Indications

No indication recorded.